Main Line Fertility Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures

BRYN MAWR, Pa., Nov. 5, 2013 /PRNewswire/ -- Main Line Fertility today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos. A novel biologic agent similar to a naturally occurring protein in the female reproductive tract, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes.

"We are delighted to be part of the Thrive-IVF Research Study to help evaluate a unique treatment option that could help improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful IVF procedures," said Michael Glassner, MD, Thrive-IVF study investigator and System Division Chief of Reproductive Endocrinology at Main Line Fertility.

More than seven million couples in the U.S. suffer from infertility and 10 percent of women of childbearing age in the developed world experience infertility in any given 12-month period. While significant research efforts in IVF have been focused on the embryo, it is estimated that three-fourths of all embryos that are transferred still fail to implant in the uterus. 

A critical part of the equation for the establishment and maintenance of a successful pregnancy is the presence not only of a good embryo, but also a favorable maternal environment for the embryo to implant and thrive. NT100's novel mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. There are currently no FDA-approved therapies focused on this critical dimension of endometrial receptivity.

"Nora believes that Main Line Fertility is an ideal partner for this important infertility study," said Jeffrey K Tong, Ph.D., President and CEO, Nora Therapeutics. "We are excited to advance our NT100 clinical program with the goal of generating the evidence needed to earn FDA approval as the first and only treatment indicated to improve pregnancy success rates and outcomes for women with a history of repeated IVF failures."

About the Thrive-IVF Research Study
The Thrive-IVF Research Study (NT-03) is a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy, safety and tolerability of NT100 in approximately 150 women 21-38 years of age who have had repeated (three or more) IVF failures despite having good-quality embryos. Study participants will be randomized to receive NT100 (low or high dose) or placebo. The study will be conducted at approximately 15-20 clinical sites in major metropolitan areas across the U.S. Visit http://www.thriveivf.com or www.clinicaltrials.gov for more information.

About Main Line Fertility
Main Line Fertility is a comprehensive fertility center located in the western suburbs of Philadelphia. We offer initial fertility evaluations including ovulation induction, insemination, and surgery. Our in vitro fertilization program (IVF) offers the latest assisted reproductive technologies, including, but not limited to, intracytoplasmic sperm injection (ICSI), preimplantation genetic diagnosis (PGD), donor egg and embryo, and elective egg freezing. Main Line Fertility is also participating in several clinical research trials that are on the cutting edge of infertility research. In 2012, Main Line Fertility Center launched a Fertility Preservation Program which assists women and men recently diagnosed with cancer preserve their fertility before undergoing cancer treatment. For more information about Main Line Fertility, visit www.mainlinefertility.com.

About Nora Therapeutics, Inc.
Nora Therapeutics, Inc., is a specialty biopharmaceutical company focused on developing therapeutics to address unmet clinical needs in reproductive medicine. Nora's lead compound, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100's mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information about Nora Therapeutics, visit www.noratherapeutics.com.

SOURCE Nora Therapeutics



RELATED LINKS
http://www.noratherapeutics.com

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.